BNR
Burning Rock Biotech LtdPrice & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BNR
this stock
Burning Rock Biotech Ltd
|
$123.92M | -46.7% | +9.2% | — | 0.4% |
|
TMO
Thermo Fisher Scientific Inc.
|
$189.58B | -11.9% | +0.4% | 28.0 | 1.2% |
|
DHR
Danaher Corp /De/
|
$135.02B | -14.8% | +8.5% | 36.8 | 1.6% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.83B | -17.9% | +10.4% | 40.9 | 2.7% |
|
NTRA
Natera, Inc.
|
$40.28B | +22.8% | -2.8% | — | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BNR | +33.0% | +16.7% | -54.2% | +28.4% | -46.7% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +32.1% | +15.3% | -61.7% | +28.3% | -56.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.